In a few short months, COVID-19 has transformed how healthcare works. It has diverted expertise and resources and changed the way patients are diagnosed and treated. Disrupted the development and delivery of medicines.
The result is a new environment for clinical trials. And while some issues may resolve in the short term, others may signal a more permanent shift.
That is why IQVIA deployed a task force dedicated to ensuring patient safety and trial continuity. We are here to help customers navigate today’s challenges and ensure your business, and your commitment to patients, remains strong.
IQVIA’s Research & Development Solutions COVID-19 task force quickly mobilized to develop a standardized approach to risk assessment for both in-flight and new trials.
Customers receive custom reports detailing risks and mitigation strategies to support trial continuity and patient safety, and to help you continue to drive healthcare forward - today.
Travel restrictions and limitations on face-to-face interactions may necessitate moving to a fully remote or hybrid decentralized trial model to help ensure continuity and compliance. IQVIA Study Hub is a cloud platform that allows patients and study teams to securely connect in a televisit. It also gives patients the ability to upload medical history or patient reported outcomes easily from their tablet, smartphone or web browser.
Patients need to stay home. Meet them there.
Some trial patients may require home-based care. Through our network of partners, IQVIA offers at-home support by trained nurses and phlebotomists, helping to reduce the risk of infection in healthcare settings.
We further support in-home visits by shipping lab supplies and investigational product to the patient or the home health nursing partner.
Whether through televisits, site visits or home-based care, IQVIA is effectively monitoring sites and patients through remote monitoring. By leveraging centralized monitoring, we are pivoting clinical trials from traditional monitoring to proven risk-based monitoring solutions, allowing a rapid mitigation strategy for COVID-19 impact. This approach includes
As more interactions are moving to virtual settings, it is critical to ensure timelines and productivity are maintained.
IQVIA’s experienced facilitators are a seamless extension of your study team, providing content creation and delivery as well as logistics and technical management.
Supported by professional trainers, behavioral strategists, medical writers and technical producers, our team has facilitated more than 1,000 virtual meetings in the past two years earning a >90% satisfaction rating.
IQVIA works closely with Q2 Solutions, a joint venture between IQVIA and Quest Diagnostics.
Q2 Solutions is fully operational and is working with multiple customers to expedite study launch for potential COVID-19 vaccines and treatments. We have also partnered with the University of Texas Medical Branch to develop an assay to help determine the effectiveness of vaccine candidates in protecting a person from COVID-19, and are collaborating with government and private healthcare companies in using our resources to support community testing efforts.
Leverage numerous infectious disease and vaccine experts using best-in-class data sources and the right sites.
We are committed to reducing the impact of COVID-19. Learn more about how we are helping.